Laboratory of Cell and Gene Therapy Institute for advanced Medical Sciences, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nisinomiya Hyogo 663-8501, Japan.

This email address is being protected from spam bots, you need Javascript enabled to view it

The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC).

The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28. A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25).

The scores of all items significantly improved along with the total score. Further, bodily pain was significantly reduced on day 28. Moreover, the rate of change in the serum prostate-specific antigen levels from day 0 to day 28 was significantly correlated with the rate of change in bodily pain.

In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC.

Written by:
Terao S, Shirakawa T, Acharya B, Miyata M, Hinata N, Tanaka K, Takenaka A, Hara I, Naoe M, Fuji K, Okegawa T, Higashihara E, Kamidono S, Fujisawa M, Gotoh A.   Are you the author?

Reference:
Anticancer Res. 2009 May;29(5):1533-7.

PubMed Abstract
PMID:19443362

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!